Why Reusable Data Matters For Future Of Pharma

Castor, a cloud-based data solution, is enabling researchers to effectively capture and integrate data from any source. CEO and founder of the company, Derk Arts, spoke to In Vivo about the importance of cohesive data for the future use of artificial intelligence in biopharma.

While studying epidemiology and medicine at the Vrije Universiteit in Amsterdam, Derk Arts realized there was no efficient application for simple and affordable data management. Founder and CEO of the business, he developed the first version of Castor’s Electronic Data Capture (EDC) tool around 2011 as a cloud solution for capturing medical research data in clinical trials.

The EDC technology enables researchers to capture high-quality, standardized data and make it available for reuse. The technology platform has more than 30,000 users across 4,000 studies. The company, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

20 May 2025

• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

16 May 2025

• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

15 May 2025

• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

13 May 2025

• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

20 May 2025

• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.